References
- Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316–20
- Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133: 463–6
- Monica ML, Jensen HG. Ocular bacteria from conjunctivitis patients: susceptibility to gatifloxacin and older fluoroquinolones. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 4–9, 2003; Ft. Lauderdale, FL
- Tepedino ME, Jensen HE. Efficacy and safety of gatifloxacin 0.3% ophthalmic solution compared with ofloxacin 0.3% for treatment of acute bacterial conjunctivitis. Poster presented at: Annual Meeting of the American Academy of Ophthalmology (AAO); October 20–23, 2002; Orlando, FL
- Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001; 51:473–7
- Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000;CD001211
- Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. New Engl J Med 2003;348(12):1112–21
- Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112\(Suppl 4):29S–33S
- Miller IM, Wittreich J, Vogel R, Cook TJ. The safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute, bacterial conjunctivitis. [The Norfloxacin-Placebo Ocular Study Group]. Eur J Ophthalmol 1992;2:58–66
- Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333–8
- Friedlaender MH. Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. CLAO J 1998;24:48–51
- Ting, N. Carry-forward analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker; 2001;103–4op
- Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003;110: 457–65